{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:09:34Z","timestamp":1767902974774,"version":"3.49.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00432-019-03044-5","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:47:36Z","timestamp":1571143656000},"page":"3021-3036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors"],"prefix":"10.1007","volume":"145","author":[{"given":"Ning","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linzhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-9553","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"3044_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40425-018-0422-y","volume":"6","author":"33rd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Washington, DC, USA, 7\u201311 November 2018","year":"2018","unstructured":"33rd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Washington, DC, USA, 7\u201311 November 2018 (2018) J Immunother Cancer 6:114. https:\/\/doi.org\/10.1186\/s40425-018-0422-y","journal-title":"J Immunother Cancer"},{"key":"3044_CR2","unstructured":"A Study of Atezolizumab in Combination with Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (IMmotion151) (2019). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02420821"},{"key":"3044_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","volume":"6","author":"A Amin","year":"2018","unstructured":"Amin A et al (2018) Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 6:109. https:\/\/doi.org\/10.1186\/s40425-018-0420-0","journal-title":"J Immunother Cancer"},{"key":"3044_CR4","doi-asserted-by":"publisher","first-page":"649 e644\u2013663 e6","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"F Arce Vargas","year":"2018","unstructured":"Arce Vargas F et al (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33:649 e644\u2013663 e644. https:\/\/doi.org\/10.1016\/j.ccell.2018.02.010","journal-title":"Cancer Cell"},{"key":"3044_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB et al (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19:405\u2013415. https:\/\/doi.org\/10.1016\/s1470-2045(18)30081-0","journal-title":"Lancet Oncol"},{"key":"3044_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/366076a0","volume":"366","author":"M Azuma","year":"1993","unstructured":"Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a 2nd ligand for Ctla-4 and Cd28. Nature 366:76\u201379. https:\/\/doi.org\/10.1038\/366076a0","journal-title":"Nature"},{"key":"3044_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66:551\u2013564. https:\/\/doi.org\/10.1007\/s00262-017-1954-6","journal-title":"Cancer Immunol Immunother"},{"key":"3044_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum IB, Smallwood CA, Siemens DR, Graham CH (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74:665\u2013674. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0992","journal-title":"Cancer Res"},{"key":"3044_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"3044_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401\u2013410. https:\/\/doi.org\/10.1038\/nrc1093","journal-title":"Nat Rev Cancer"},{"key":"3044_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603. https:\/\/doi.org\/10.1038\/nrc2442","journal-title":"Nat Rev Cancer"},{"key":"3044_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/s1470-2045(10)70203-5","volume":"11","author":"KC Bible","year":"2010","unstructured":"Bible KC et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962\u2013972. https:\/\/doi.org\/10.1016\/s1470-2045(10)70203-5","journal-title":"Lancet Oncol"},{"key":"3044_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54:307\u2013314. https:\/\/doi.org\/10.1007\/s00262-004-0593-x","journal-title":"Cancer Immunol Immunother"},{"key":"3044_CR14","first-page":"59","volume":"30","author":"AB Bourla","year":"2016","unstructured":"Bourla AB, Zamarin D (2016) Immunotherapy: new strategies for the treatment of gynecologic malignancies. Oncology 30:59\u201366, 69","journal-title":"Oncology"},{"key":"3044_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319\u2013328. https:\/\/doi.org\/10.1016\/s0140-6736(14)60421-9","journal-title":"Lancet"},{"key":"3044_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56\u201366","journal-title":"Lancet"},{"key":"3044_CR17","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","volume":"162","author":"MC Brunner","year":"1999","unstructured":"Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP (1999) CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 162:5813\u20135820","journal-title":"J Immunol"},{"key":"3044_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research N","year":"2013","unstructured":"Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43\u201349. https:\/\/doi.org\/10.1038\/nature12222","journal-title":"Nature"},{"key":"3044_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299\u2013309. https:\/\/doi.org\/10.1016\/j.ccr.2005.09.005","journal-title":"Cancer Cell"},{"key":"3044_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565\u2013594. https:\/\/doi.org\/10.1146\/annurev.immunol.19.1.565","journal-title":"Annu Rev Immunol"},{"key":"3044_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173:945\u2013954","journal-title":"J Immunol"},{"key":"3044_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"3044_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27:409\u2013416. https:\/\/doi.org\/10.1093\/annonc\/mdv615","journal-title":"Ann Oncol"},{"key":"3044_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334. https:\/\/doi.org\/10.1016\/s1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"key":"3044_CR25","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","volume":"25","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK et al (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25:2178\u20132184. https:\/\/doi.org\/10.1093\/annonc\/mdu445","journal-title":"Ann Oncol"},{"key":"3044_CR26","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1510016","journal-title":"N Engl J Med"},{"key":"3044_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s1470-2045(18)30107-4","volume":"19","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK et al (2018) Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol 19:451\u2013460. https:\/\/doi.org\/10.1016\/s1470-2045(18)30107-4","journal-title":"Lancet Oncol"},{"key":"3044_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M (2013) VEGFA and tumour angiogenesis. J Intern Med 273:114\u2013127. https:\/\/doi.org\/10.1111\/joim.12019","journal-title":"J Intern Med"},{"key":"3044_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","volume":"17","author":"AV Collins","year":"2002","unstructured":"Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201\u2013210","journal-title":"Immunity"},{"key":"3044_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.gde.2010.10.008","volume":"21","author":"K De Bock","year":"2011","unstructured":"De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21:73\u201379. https:\/\/doi.org\/10.1016\/j.gde.2010.10.008","journal-title":"Curr Opin Genet Dev"},{"key":"3044_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295\u2013302. https:\/\/doi.org\/10.1016\/s0140-6736(12)61857-1","journal-title":"Lancet"},{"key":"3044_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/107327481402100308","volume":"21","author":"DE Dolan","year":"2014","unstructured":"Dolan DE, Gupta S (2014) PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control J Moffitt Cancer Center 21:231\u2013237. https:\/\/doi.org\/10.1177\/107327481402100308","journal-title":"Cancer Control J Moffitt Cancer Center"},{"key":"3044_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s1074-7613(01)00259-x","volume":"16","author":"JG Egen","year":"2002","unstructured":"Egen JG, Allison JP (2002) Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16:23\u201335. https:\/\/doi.org\/10.1016\/s1074-7613(01)00259-x","journal-title":"Immunity"},{"key":"3044_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ni0702-611","volume":"3","author":"JG Egen","year":"2002","unstructured":"Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611\u2013618. https:\/\/doi.org\/10.1038\/ni0702-611","journal-title":"Nat Immunol"},{"key":"3044_CR35","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639\u20133646. https:\/\/doi.org\/10.1200\/JCO.2012.48.4659","journal-title":"J Clin Oncol"},{"key":"3044_CR36","doi-asserted-by":"publisher","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B et al (2016) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v58\u2013v68. https:\/\/doi.org\/10.1093\/annonc\/mdw328","journal-title":"Ann Oncol"},{"key":"3044_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1084\/jem.188.1.205","volume":"188","author":"F Fallarino","year":"1998","unstructured":"Fallarino F, Fields PE, Gajewski TF (1998) B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med 188:205\u2013210","journal-title":"J Exp Med"},{"key":"3044_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1084\/jem.2008181120409c","volume":"206","author":"F Fallarino","year":"2009","unstructured":"Fallarino F et al (2009) CD4(+) regulatory T cells require CTLA-4 for the maintenance of systemic tolerance (vol 206, pg 421, 2009). J Exp Med 206:720. https:\/\/doi.org\/10.1084\/jem.2008181120409c","journal-title":"J Exp Med"},{"key":"3044_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795\u2013803. https:\/\/doi.org\/10.1038\/nrc909","journal-title":"Nat Rev Cancer"},{"key":"3044_CR40","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967\u2013974. https:\/\/doi.org\/10.1038\/nature04483","journal-title":"Nature"},{"key":"3044_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"key":"3044_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328\u2013335. https:\/\/doi.org\/10.1016\/j.bbrc.2005.05.132","journal-title":"Biochem Biophys Res Commun"},{"key":"3044_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.133.2.275","volume":"133","author":"J Folkman","year":"1971","unstructured":"Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275\u2013288","journal-title":"J Exp Med"},{"key":"3044_CR44","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015\u20133029. https:\/\/doi.org\/10.1084\/jem.20090847","journal-title":"J Exp Med"},{"key":"3044_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065x.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242. https:\/\/doi.org\/10.1111\/j.1600-065x.2010.00923.x","journal-title":"Immunol Rev"},{"key":"3044_CR46","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1126\/science.7694363","volume":"262","author":"GJ Freeman","year":"1993","unstructured":"Freeman GJ et al (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909\u2013911","journal-title":"Science"},{"key":"3044_CR47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027\u20131034","journal-title":"J Exp Med"},{"key":"3044_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(13)61719-5","journal-title":"Lancet"},{"key":"3044_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253\u2013268. https:\/\/doi.org\/10.1038\/nri3175","journal-title":"Nat Rev Immunol"},{"key":"3044_CR50","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1758834012467661","volume":"5","author":"A Garcia","year":"2013","unstructured":"Garcia A, Singh H (2013) Bevacizumab and ovarian cancer. Therap Adv Med Oncol 5:133\u2013141. https:\/\/doi.org\/10.1177\/1758834012467661","journal-title":"Therap Adv Med Oncol"},{"key":"3044_CR51","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(14)60845-x","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665\u2013673. https:\/\/doi.org\/10.1016\/s0140-6736(14)60845-x","journal-title":"Lancet"},{"key":"3044_CR52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud G, Lesourne R, Love PE (2018) Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol 18:485\u2013497. https:\/\/doi.org\/10.1038\/s41577-018-0020-8","journal-title":"Nat Rev Immunol"},{"key":"3044_CR53","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","volume":"30","author":"S George","year":"2012","unstructured":"George S et al (2012) Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 30:2401\u20132407. https:\/\/doi.org\/10.1200\/JCO.2011.39.9394","journal-title":"J Clin Oncol"},{"key":"3044_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra JR et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85\u201390. https:\/\/doi.org\/10.1038\/ng0594-85","journal-title":"Nat Genet"},{"key":"3044_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41577-018-0009-3","volume":"18","author":"P Golstein","year":"2018","unstructured":"Golstein P, Griffiths GM (2018) An early history of T cell-mediated cytotoxicity. Nat Rev Immunol 18:527\u2013535. https:\/\/doi.org\/10.1038\/s41577-018-0009-3","journal-title":"Nat Rev Immunol"},{"key":"3044_CR56","first-page":"3776","volume":"59","author":"G Griffon-Etienne","year":"1999","unstructured":"Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776\u20133782","journal-title":"Cancer Res"},{"key":"3044_CR57","first-page":"5","volume":"13","author":"JF Grosso","year":"2013","unstructured":"Grosso JF, Jure-Kunkel MN (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunity 13:5","journal-title":"Cancer Immunity"},{"key":"3044_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(12)61900-x","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/s0140-6736(12)61900-x","journal-title":"Lancet"},{"key":"3044_CR59","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+\u2009T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360\u20133365. https:\/\/doi.org\/10.1073\/pnas.0611533104","journal-title":"Proc Natl Acad Sci USA"},{"key":"3044_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370","journal-title":"Cell"},{"key":"3044_CR61","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.7694361","volume":"262","author":"KS Hathcock","year":"1993","unstructured":"Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ (1993) Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905\u2013907","journal-title":"Science"},{"key":"3044_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00621","author":"SA Hendry","year":"2016","unstructured":"Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB (2016) The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2016.00621","journal-title":"Front Immunol"},{"key":"3044_CR63","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567. https:\/\/doi.org\/10.1038\/nature14011","journal-title":"Nature"},{"key":"3044_CR64","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"3044_CR65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS et al (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2:632\u2013642. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0053","journal-title":"Cancer Immunol Res"},{"key":"3044_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W (2018) Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18:195\u2013203. https:\/\/doi.org\/10.1038\/nri.2017.145","journal-title":"Nat Rev Immunol"},{"key":"3044_CR67","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"EF Hui","year":"2017","unstructured":"Hui EF et al (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355:1428. https:\/\/doi.org\/10.1126\/science.aaf1292","journal-title":"Science"},{"key":"3044_CR68","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/13543784.2016.1156857","volume":"25","author":"SP Ivy","year":"2016","unstructured":"Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC (2016) Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs 25:597\u2013611. https:\/\/doi.org\/10.1517\/13543784.2016.1156857","journal-title":"Expert Opin Investig Drugs"},{"key":"3044_CR69","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987\u2013989. https:\/\/doi.org\/10.1038\/nm0901-987","journal-title":"Nat Med"},{"key":"3044_CR70","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31:2205\u20132218. https:\/\/doi.org\/10.1200\/JCO.2012.46.3653","journal-title":"J Clin Oncol"},{"key":"3044_CR71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605\u2013622. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006","journal-title":"Cancer Cell"},{"key":"3044_CR72","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/Bf00437472","volume":"15","author":"RK Jain","year":"1996","unstructured":"Jain RK, Koenig GC, Dellian M, Fukumura D, Munn LL, Melder RJ (1996) Leukocyte\u2013endothelial adhesion and angiogenesis in tumors. Cancer Metast Rev 15:195\u2013204. https:\/\/doi.org\/10.1007\/Bf00437472","journal-title":"Cancer Metast Rev"},{"key":"3044_CR73","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-bioeng-071813-105259","volume":"16","author":"RK Jain","year":"2014","unstructured":"Jain RK, Martin JD, Stylianopoulos T (2014) The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 16:321\u2013346. https:\/\/doi.org\/10.1146\/annurev-bioeng-071813-105259","journal-title":"Annu Rev Biomed Eng"},{"key":"3044_CR74","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388:518\u2013529. https:\/\/doi.org\/10.1016\/S0140-6736(15)01088-0","journal-title":"Lancet"},{"key":"3044_CR75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/83144","volume":"2","author":"LP Kane","year":"2001","unstructured":"Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A (2001) Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not T(H)2 cytokines. Nat Immunol 2:37\u201344. https:\/\/doi.org\/10.1038\/83144","journal-title":"Nat Immunol"},{"key":"3044_CR76","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/1535-7163.mct-10-0876","volume":"10","author":"J Kendrew","year":"2011","unstructured":"Kendrew J et al (2011) An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding. Mol Cancer Ther 10:770\u2013783. https:\/\/doi.org\/10.1158\/1535-7163.mct-10-0876","journal-title":"Mol Cancer Ther"},{"key":"3044_CR77","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever RM et al (2017) Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171:1301. https:\/\/doi.org\/10.1016\/j.cell.2017.11.013","journal-title":"Cell"},{"key":"3044_CR78","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/jco.2010.32.4145","volume":"29","author":"R Kurzrock","year":"2011","unstructured":"Kurzrock R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660\u20132666. https:\/\/doi.org\/10.1200\/jco.2010.32.4145","journal-title":"J Clin Oncol"},{"key":"3044_CR79","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"E Lanitis","year":"2015","unstructured":"Lanitis E, Irving M, Coukos G (2015) Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol 33:55\u201363. https:\/\/doi.org\/10.1016\/j.coi.2015.01.011","journal-title":"Curr Opin Immunol"},{"key":"3044_CR80","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261\u2013268. https:\/\/doi.org\/10.1038\/85330","journal-title":"Nat Immunol"},{"key":"3044_CR81","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F et al (1993) Identification of the von Hippel\u2013Lindau disease tumor suppressor gene. Science 260:1317\u20131320","journal-title":"Science"},{"key":"3044_CR82","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"JM Lee","year":"2017","unstructured":"Lee JM et al (2017) Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1\u20133 inhibitor cediranib in women\u2019s cancers: a dose-escalation, phase i study. J Clin Oncol 35:2193\u20132202. https:\/\/doi.org\/10.1200\/JCO.2016.72.1340","journal-title":"J Clin Oncol"},{"key":"3044_CR83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","volume":"26","author":"D Liao","year":"2007","unstructured":"Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metast Rev 26:281\u2013290. https:\/\/doi.org\/10.1007\/s10555-007-9066-y","journal-title":"Cancer Metast Rev"},{"key":"3044_CR84","doi-asserted-by":"publisher","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","volume":"13","author":"WM Linehan","year":"2007","unstructured":"Linehan WM et al (2007) Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Can Res 13:671s\u2013679s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1870","journal-title":"Clin Can Res"},{"key":"3044_CR85","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","volume":"87","author":"PS Linsley","year":"1990","unstructured":"Linsley PS, Clark EA, Ledbetter JA (1990) T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1. Proc Natl Acad Sci USA 87:5031\u20135035","journal-title":"Proc Natl Acad Sci USA"},{"key":"3044_CR86","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561\u2013569","journal-title":"J Exp Med"},{"key":"3044_CR87","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","volume":"1","author":"PS Linsley","year":"1994","unstructured":"Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793\u2013801","journal-title":"Immunity"},{"key":"3044_CR88","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.ccr-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17:6958\u20136962. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-1595","journal-title":"Clin Cancer Res"},{"key":"3044_CR89","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913\u2013924. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.005","journal-title":"Eur Urol"},{"key":"3044_CR90","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-017-0511-2","volume":"10","author":"J Long","year":"2017","unstructured":"Long J et al (2017) PD-1\/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol 10:146. https:\/\/doi.org\/10.1186\/s13045-017-0511-2","journal-title":"J Hematol Oncol"},{"key":"3044_CR91","first-page":"1","volume":"36","author":"V Makker","year":"2018","unstructured":"Makker V (2018) Lenvatinib\u2009+\u2009pembrolizumab in patients with advanced endometrial cancer: updated results. J Clin Oncol 36:1","journal-title":"J Clin Oncol"},{"key":"3044_CR92","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.4049\/jimmunol.164.10.5319","volume":"164","author":"EL Masteller","year":"2000","unstructured":"Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164:5319\u20135327","journal-title":"J Immunol"},{"key":"3044_CR93","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF et al (2018) Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 24:749\u2013757. https:\/\/doi.org\/10.1038\/s41591-018-0053-3","journal-title":"Nat Med"},{"key":"3044_CR94","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1158\/0008-5472.can-17-2176","volume":"78","author":"L Meder","year":"2018","unstructured":"Meder L et al (2018) Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res 78:4270\u20134281. https:\/\/doi.org\/10.1158\/0008-5472.can-17-2176","journal-title":"Cancer Res"},{"key":"3044_CR95","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nm0996-992","volume":"2","author":"RJ Melder","year":"1996","unstructured":"Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK (1996) During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2:992\u2013997. https:\/\/doi.org\/10.1038\/nm0996-992","journal-title":"Nat Med"},{"key":"3044_CR96","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607\u2013615. https:\/\/doi.org\/10.1038\/nm.3541","journal-title":"Nat Med"},{"key":"3044_CR97","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370:1769\u20131770. https:\/\/doi.org\/10.1056\/NEJMc1400731","journal-title":"N Engl J Med"},{"key":"3044_CR98","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ et al (2015a) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"3044_CR99","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/s1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ et al (2015b) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473\u20131482. https:\/\/doi.org\/10.1016\/s1470-2045(15)00290-9","journal-title":"Lancet Oncol"},{"key":"3044_CR100","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"3044_CR101","doi-asserted-by":"publisher","first-page":"v295","DOI":"10.1093\/annonc\/mdx371","volume":"28","author":"R Nadal","year":"2017","unstructured":"Nadal R et al (2017) Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Ann Oncol 28:v295\u2013v329. https:\/\/doi.org\/10.1093\/annonc\/mdx371","journal-title":"Ann Oncol"},{"key":"3044_CR102","unstructured":"NCCN Clinical Practice Guidelines in Oncology-Kidney Cancer (Version 4.2019)"},{"key":"3044_CR103","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(13)70401-7","volume":"14","author":"AK Nowak","year":"2013","unstructured":"Nowak AK (2013) Immunological checkpoint inhibitors enter adolescence. Lancet Oncol 14:1035\u20131037. https:\/\/doi.org\/10.1016\/S1470-2045(13)70401-7","journal-title":"Lancet Oncol"},{"key":"3044_CR104","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/369327a0","volume":"369","author":"F Pages","year":"1994","unstructured":"Pages F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, Olive D (1994) Binding of phosphatidylinositol-3-Oh kinase to Cd28 is required for T-cell signaling. Nature 369:327\u2013329. https:\/\/doi.org\/10.1038\/369327a0","journal-title":"Nature"},{"key":"3044_CR105","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1200\/JCO.2017.35.6_suppl.349","volume":"35","author":"DP Petrylak","year":"2017","unstructured":"Petrylak DP et al (2017) A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): interim safety and clinical activity in patients with urothelial carcinoma. J Clin Oncol 35:349. https:\/\/doi.org\/10.1200\/JCO.2017.35.6_suppl.349","journal-title":"J Clin Oncol"},{"key":"3044_CR106","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372\u20138377. https:\/\/doi.org\/10.1073\/pnas.1533209100","journal-title":"Proc Natl Acad Sci USA"},{"key":"3044_CR107","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS et al (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600\u2013603. https:\/\/doi.org\/10.1126\/science.1202947","journal-title":"Science"},{"key":"3044_CR108","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","volume":"20","author":"RR Ramjiawan","year":"2017","unstructured":"Ramjiawan RR, Griffioen AW, Duda DG (2017) Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis 20:185\u2013204. https:\/\/doi.org\/10.1007\/s10456-017-9552-y","journal-title":"Angiogenesis"},{"key":"3044_CR109","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","volume":"177","author":"S Read","year":"2006","unstructured":"Read S et al (2006) Blockade of CTLA-4 on CD4(+) CD25(+) regulatory T cells abrogates their function in vivo. J Immunol 177:4376\u20134383. https:\/\/doi.org\/10.4049\/jimmunol.177.7.4376","journal-title":"J Immunol"},{"key":"3044_CR110","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350","journal-title":"Science"},{"key":"3044_CR111","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/s0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931\u20131939. https:\/\/doi.org\/10.1016\/s0140-6736(11)61613-9","journal-title":"Lancet"},{"key":"3044_CR112","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"3044_CR113","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","volume":"30","author":"E Tartour","year":"2011","unstructured":"Tartour E et al (2011) Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metast Rev 30:83\u201395. https:\/\/doi.org\/10.1007\/s10555-011-9281-4","journal-title":"Cancer Metast Rev"},{"key":"3044_CR114","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.can-15-0255","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75:2139\u20132145. https:\/\/doi.org\/10.1158\/0008-5472.can-15-0255","journal-title":"Cancer Res"},{"key":"3044_CR115","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:17174\u201317179. https:\/\/doi.org\/10.1073\/pnas.0406351101","journal-title":"Proc Natl Acad Sci USA"},{"key":"3044_CR116","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.can-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381\u20133385. https:\/\/doi.org\/10.1158\/0008-5472.can-05-4303","journal-title":"Cancer Res"},{"key":"3044_CR117","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.ccr-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13:1757\u20131761. https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-2599","journal-title":"Clin Cancer Res"},{"key":"3044_CR118","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L et al (2017) Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544:250\u2013254. https:\/\/doi.org\/10.1038\/nature21724","journal-title":"Nature"},{"key":"3044_CR119","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.1073\/pnas.1518808112","volume":"112","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM et al (2015) Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci USA 112:14325\u201314330. https:\/\/doi.org\/10.1073\/pnas.1518808112","journal-title":"Proc Natl Acad Sci USA"},{"key":"3044_CR120","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207\u2013212. https:\/\/doi.org\/10.1016\/j.coi.2011.12.009","journal-title":"Curr Opin Immunol"},{"key":"3044_CR121","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell 27:450\u2013461. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001","journal-title":"Cancer cell"},{"key":"3044_CR122","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","volume":"185","author":"PA van der Merwe","year":"1997","unstructured":"van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ (1997) CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185:393\u2013403","journal-title":"J Exp Med"},{"key":"3044_CR123","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment Nature reviews. Cancer 12:237\u2013251. https:\/\/doi.org\/10.1038\/nrc3237","journal-title":"Cancer"},{"key":"3044_CR124","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T et al (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8(+) T cells in tumors. J Exp Med 212:139\u2013148. https:\/\/doi.org\/10.1084\/jem.20140559","journal-title":"J Exp Med"},{"key":"3044_CR125","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2018.36.15_suppl.4524","volume":"36","author":"J Vuky","year":"2018","unstructured":"Vuky J (2018) Updated efficacy and safety of KEYNOTE-052: a single arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol 36:4524","journal-title":"J Clin Oncol"},{"key":"3044_CR126","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","volume":"1","author":"TL Walunas","year":"1994","unstructured":"Walunas TL et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405\u2013413","journal-title":"Immunity"},{"key":"3044_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0403-5","author":"J Wang","year":"2017","unstructured":"Wang J, Yuan RR, Song WR, Sun JW, Liu DL, Li ZH (2017) PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-017-0403-5","journal-title":"J Hematol Oncol"},{"key":"3044_CR128","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"3044_CR129","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/jco.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134\u2013141. https:\/\/doi.org\/10.1200\/jco.2011.35.5040","journal-title":"J Clin Oncol"},{"key":"3044_CR130","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/s1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235. https:\/\/doi.org\/10.1016\/s1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"key":"3044_CR131","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/s1535-6108(04)00305-8","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler F et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metal loproteinases. Cancer Cell 6:553\u2013563. https:\/\/doi.org\/10.1016\/s1535-6108(04)00305-8","journal-title":"Cancer Cell"},{"key":"3044_CR132","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J et al (2019) Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res 25:515\u2013523. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2484","journal-title":"Clin Cancer Res"},{"key":"3044_CR133","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.devcel.2016.03.015","volume":"37","author":"WL Ye","year":"2016","unstructured":"Ye WL (2016) The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev Cell 37:114\u2013125. https:\/\/doi.org\/10.1016\/j.devcel.2016.03.015","journal-title":"Dev Cell"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03044-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T18:02:22Z","timestamp":1695319342000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":133,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03044-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}